Education
About Us
Working with TipRanks
Follow Us
Myomo Inc (MYO)
:MYO
MYO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.76 - $7.17
Previous CloseN/A
Volume192.17K
Average Volume (3M)291.05K
Market Cap
$171.62M
Enterprise ValueN/A
Total Cash (Recent Filing)$24.87M
Total Debt (Recent Filing)$8.11M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 06, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding35,978,650
10 Day Avg. Volume279,601
30 Day Avg. Volume291,054
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)7.57
Price to Sales (P/S)0.00
P/FCF Ratio-39.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.13Price Target Upside185.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Myomo News
PremiumCompany Announcements
Myomo Inc Reports Strong Q1 Revenue Amid Challenges
PremiumCompany Announcements
Myomo Reports Strong Q1 2025 Revenue GrowthPremiumCompany Announcements
Myomo Announces Board Transition with Director Departures---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMYO reported 1Q25 results with revenue up 162% year-over-year, above 1Q25 guidance, consensus, and analyst's estimate.
Market ExpansionThe Medicare Part B population has become a significant and growing portion of patients and revenue, viewed positively by the analysts.
Strategic GrowthManagement plans to scale up the company’s commercial operations, expand its new manufacturing facility, and increase the advertising budget to $6M for the year, double that of 2024.
Bears Say
Operational ChallengesThe change to Meta’s guidelines to the sharing of personal health information on Facebook resulted in fewer potential patients added to the pipeline during the first quarter.
Regulatory And Payer ChallengesReduced authorizations from Medicare Advantage payers as well as private payers during the quarter resulted in numerous appeals as well as delays.
Revenue GuidanceManagement introduced lower-than-expected 2Q25 revenue guidance of $9.0M–$9.5M, below prior at-consensus estimate.
---
Ownership Overview
16.18% Insiders
5.74% Mutual Funds
1.03% Other Institutional Investors
73.34% Public Companies and
Individual Investors
MYO FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was $2.76 and its highest was $7.17 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is $171.62M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Aug 06, 2025 which is in 86 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on May 07, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.076 by -$0.004.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.1.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 35,978,650 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.076. Following the earnings report the stock price went down -30.579%.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in MYO
---
Myomo Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.13 (185.31% Upside)
$9.13 (185.31% Upside)
Blogger Sentiment
Bullish
MYO Sentiment 75%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $383.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.06%
12-Months-Change
Fundamentals
Return on Equity
-35.68%
Trailing 12-Months
Asset Growth
189.71%
Trailing 12-Months
Company Description
Myomo Inc
Myomo, Inc. (MYO) is a medical robotics company that specializes in the development and commercialization of powered orthotic devices to improve mobility for individuals with neurological disorders and upper-limb paralysis. The company's flagship product, the MyoPro, is a lightweight, wearable robotic device designed to restore the ability to perform activities of daily living to individuals who have suffered strokes, brachial plexus injuries, or other neuromuscular disorders. Myomo operates primarily in the healthcare sector, focusing on rehabilitation and assistive technology.
---
MYO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and promising developments in the O&P channel and international markets. However, the company faced challenges in lead generation due to changes in Meta's policies and high denial rates from Medicare Advantage plans, which impacted the authorization rate and operating expenses. Despite these challenges, the company maintained its full-year guidance and showed confidence in overcoming these hurdles.Read More>---
MYO Stock 12 Month Forecast
Average Price Target
$9.13
▲(185.31% Upside)
Technical Analysis
---